Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease

Headache

Volumn 52, Issue 2, 2012, Pages 224-235

  Ho, Tony W ^a   Ho, Andrew P ^a   Chaitman, Bernard R ^b   Johnson, Constance ^c   Mathew, Ninan T ^d   Kost, James ^a   Fan, Xiaoyin ^a   Aurora, Sheena K ^e   Brandes, Jan L ^f   Fei, Kaiyin ^a   Beebe, Louise ^a   Lines, Christopher ^a   Krucoff, Mitchell W ^g  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Headache Care Center   (United States)

^d Houston Headache Clinic   (United States)

^e Swedish Headache Center   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cardiovascular; CGRP; migraine; telcagepant

Indexed keywords

AMINOTRANSFERASE; PARACETAMOL; TELCAGEPANT;

ACUTE DISEASE; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AZEPINES; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MODELS, STATISTICAL; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84857047327     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.02052.x     Document Type: Article

References (33)

1. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J,. CGRP may play a causative role in migraine. Cephalalgia. 2002; 22: 54-61. (Pubitemid 34626025)
2. Arulmani U, MaassenVanDenBrink A, Villalõn CM, Saxena PR,. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol. 2004; 500: 315-330. (Pubitemid 39304018)
3. Goadsby PJ,. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs. 2005; 65: 2557-2567. (Pubitemid 43049952)
4. Ho TW, Edvinsson L, Goadsby PJ,. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010; 6: 573-582.
5. Edvinsson L, Linde M,. New drugs in migraine treatment and prophylaxis: Telcagepant and topiramate. Lancet. 2010; 376: 645-655.
6. Olesen J, Diener HC, Husstedt IW, et al,. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350: 1104-1110. (Pubitemid 38298990)
7. Ho TW, Mannix LK, Fan X, et al,. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312. (Pubitemid 351550355)
8. Ho TW, Ferrari MD, Dodick DW, et al,. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123.
9. Connor KM, Shapiro RE, Diener HC, et al,. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977.
10. Brain SD, Grant AD,. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. 2004; 84: 903-934. (Pubitemid 38823770)
11. Petersen KA, Birk S, Lassen LH, et al,. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005; 25: 139-147. (Pubitemid 40193957)
12. Sinclair SR, Kane SA, Van der Schueren BJ, et al,. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br J Clin Pharmacol. 2010; 69: 15-22.
13. Blanchard R, Rowe J, Palcza J, et al,. High dose telcagepant has no effect on 24-hr ambulatory blood pressure or heart rate in healthy volunteers. Headache. 2010; 50 (Suppl. 1): S35-S36. (Abstract).
14. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ,. Oral triptans (serotonin 5-HT-1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001; 358: 1668-1675. (Pubitemid 33124324)
15. Dodick D, Lipton RB, Martin V, et al,. Consensus statement: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache. 2004; 44: 414-425. (Pubitemid 38685549)
16. Mair J, Lechleitner P, Längle T, Wiedermann C, Dienstl F, Saria A,. Plasma CGRP in acute myocardial infarction. Lancet. 1990; 335: 168. (Pubitemid 20032764)
17. Burley DS, Hamid SA, Baxter GF,. Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail Rev. 2007; 12: 279-291. (Pubitemid 350176701)
18. Chan KY, Vermeersch S, de Hoon J, Villalõn CM, Maassenvandenbrink A,. Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects. Pharmacol Ther. 2011; 129: 332-351.
19. Lynch JJ, Regan CP, Edvinsson L, Hargreaves RJ, Kane SA,. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries. J Cardiovasc Pharmacol. 2010; 55: 518-521.
20. Edvinsson L, Chan KY, Eftekhari S, et al,. Effect of the CGRP receptor antagonist telcagepant in human cranial arteries. Cephalalgia. 2010; 30: 1233-1240.
21. Chan KY, Edvinsson L, Eftekhari S, et al,. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010; 334: 746-752.
22. Shen Y-T, Mallee JJ, Handt LK, et al,. Effects of inhibition of α-CGRP receptors on cardiac and peripheral vascular dynamics in conscious dogs with chronic heart failure. J Cardiovasc Pharmacol 2003; 42: 656-661. (Pubitemid 37305985)
23. Regan CP, Stump GL, Kane SA, Lynch JJ Jr,. Calcitonin gene-related peptide receptor antagonism does not affect the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis. J Pharmacol Exp Ther. 2009; 328: 571-578.
24. 8-37 on myocardial reactive hyperemic response in conscious dogs. Eur J Pharmacol. 2009; 623: 96-102.
25. Van der Schueren BJ, Blanchard R, Murphy MG, et al,. Effect of MK-0974, an oral CGRP antagonist, on the hemodynamic response to sublingual nitroglycerin. Headache. 2008; 48 (Suppl. 1): S63-S64. (Abstract).
26. Behm MO, Blanchard RL, Murphy MG, et al,. Effect of telcagepant on spontaneous ischemia in cardiovascular patients in a randomized study. Headache. 2011; 51: 954-960.
27. Chaitman BR, Ho AP, Behm MO, et al,. The calcitonin gene-related peptide receptor antagonist teclagepant does not reduce exercise tolerance in patients with exercise induced myocardial ischemia. J Am Coll Cardiol. 2010; 55 (Suppl. 1): A100.E939. (Abstract).
28. Elkind AH, Satin LZ, Nila A, Keywood C,. Frovatriptan use in migraineurs with or at high risk of coronary artery disease. Headache. 2004; 44: 403-410. (Pubitemid 38685547)
29. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004; 24: 9-160.
30. Bigal ME, Kurth T, Santanello N, et al,. Migraine and cardiovascular disease: A population-based study. Neurology. 2010; 74: 628-635.
31. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM,. Severe vascular events in migraine patients. Headache. 2004; 44: 642-651. (Pubitemid 38931894)
32. Goadsby PJ, Sprenger T,. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010; 9: 285-298.
33. Gales BJ, Bailey EK, Reed AN, Gales MA,. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann Pharmacother. 2010; 44: 360-366.